Bar-Sela Gil, Gershony Avishay, Haim Nissim
Department of Oncology, Rambam Medical Center and Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Harefuah. 2006 Jan;145(1):42-6, 77.
Extracts and preparations from the parasitic plant mistletoe (Viscum album L.) have been used in the treatment of cancer for decades. Mistletoe treatment for cancer was introduced in 1920 by Steiner and Wegman, founders of the Anthroposophical medical method. Today, mistletoe extracts are the most frequently prescribed unconventional cancer therapies in Germany, as in some other European countries. Full clinical data about the efficacy of the mistletoe preparations is still missing. The preparations are usually given as subcutaneous injections, but other routes of administration are also used. Numerous preclinical and in-vitro studies have reported immunostimulatory, cytotoxic and proapoptotic effects. More than 15 prospective clinical trials using mistletoe extracts in patients with different malignancies have been reported. In most of these studies the authors reported that mistletoe extracts had therapeutic benefit in terms of response rate, overall survival, quality of life and reduction in side-effects of the oncological treatment. Unfortunately, almost all of these reported studies had at least one major weakness that questioned their reliability. Side effects of the different mistletoe preparation used in human studies are generally minimal and non-life threatening. In the current review recent studies, including two phase II studies from our center, are included. In the future, data that will be obtained from good quality studies might facilitate reaching firm conclusions regarding the therapeutic benefit of mistletoe preparation for oncological treatment.
寄生植物槲寄生(Viscum album L.)的提取物和制剂用于癌症治疗已有数十年历史。1920年,人智医学方法的创始人施泰纳(Steiner)和韦格曼(Wegman)首次将槲寄生用于癌症治疗。如今,与其他一些欧洲国家一样,槲寄生提取物是德国最常处方的非常规癌症疗法。关于槲寄生制剂疗效的完整临床数据仍然缺失。这些制剂通常通过皮下注射给药,但也使用其他给药途径。大量临床前和体外研究报告了其免疫刺激、细胞毒性和促凋亡作用。已有超过15项使用槲寄生提取物治疗不同恶性肿瘤患者的前瞻性临床试验报告。在大多数这些研究中,作者报告称,槲寄生提取物在缓解率、总生存期、生活质量以及减少肿瘤治疗副作用方面具有治疗益处。不幸的是,几乎所有这些报告的研究都至少有一个严重缺陷,这质疑了它们的可靠性。在人体研究中使用的不同槲寄生制剂的副作用通常很小,不会危及生命。在本综述中纳入了近期的研究,包括我们中心的两项II期研究。未来,从高质量研究中获得的数据可能有助于就槲寄生制剂对肿瘤治疗的益处得出确凿结论。